^
Association details:
| Biomarker: | EGFR overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | BB-1705 (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6349 / 25 - Preclinical studies of BB-1705: An EGFR-targeting eribulin-containing ADC with an affinity optimized antibody to minimize potential toxicities to normal tissues
Published date:
03/15/2023
Excerpt:
In vitro cytotoxicity study showed that BB-1705 had high potency to a panel of cancer cell lines with medium to high EGFR expression levels….This data support BB-1705 as a potent antitumor agent to EGFR medium to high-expressing cancers and warrant further investigation of BB-1705 in human clinic trials.
